<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04132414</url>
  </required_header>
  <id_info>
    <org_study_id>31-175 ex 18/19</org_study_id>
    <nct_id>NCT04132414</nct_id>
  </id_info>
  <brief_title>Cerebral NIRS Monitoring During Anesthesia in Neonates and Infants</brief_title>
  <official_title>Monitoring Of REgional Cerebral Oxygenation (rcSO2 ) With Near INFrared SpectrOscopy (NIRS) During Non-cardiac Surgery in Preterms, Neonates and Infants in Addition to Standard Monitoring to Guide Intraoperative Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The brain is a very vulnerable organ, especially in premature babies, newborns and infants.
      However, during anesthesia, the oxygenation of the brain can only be monitored indirectly and
      insufficiently. Near-infrared spectroscopy (NIRS) is an established monitoring method in
      other areas (e.g., neonatology, cardiac anesthesia), which provides non-invasive information
      about the regional oxygen supply of the brain. The integration of this monitoring device into
      the anaesthesiological care for neonates and infants could reduce the risk of cerebral
      hypoxia. The planned study investigates whether the use of NIRS in anesthetized children up
      to 6 months can prevent or influence the occurrence of cerebral hypoxia.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2019</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cerebral hypoxic burden</measure>
    <time_frame>1 day</time_frame>
    <description>Time under 65% cerebral oxygen saturation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fluid administration</measure>
    <time_frame>1 day</time_frame>
    <description>ml/kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Vasopressor or Inotrope administered</measure>
    <time_frame>1 day</time_frame>
    <description>Proportion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with erythrocyte administration</measure>
    <time_frame>1 day</time_frame>
    <description>Proportion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of inspired oxygen</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cerebral Oxygenation</condition>
  <arm_group>
    <arm_group_label>NIRS open</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cerebral NIRS monitoring applied and visible to caregiver. Interventions according to protocol in phases of cerebral hypoxia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NIRS blinded</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>NIRS monitoring applied and masked for caregiver.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>NIRS open</intervention_name>
    <description>Treatment according to protocol in phases of cerebral hypoxia.</description>
    <arm_group_label>NIRS open</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Expected duration of Anesthesia &gt;45 minutes

          -  Intervention/surgery in the operating room

        Exclusion Criteria:

          -  Impossibility to place cerebral NIRS sensor

          -  Known cerebral pathology

          -  Missing parental consent

          -  Congenial cardiac condition with right to left shunt

          -  Cardiac surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Heschl, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan Heschl, M.D., Ph.D.</last_name>
    <phone>+4331638513027</phone>
    <email>stefan.heschl@medunigraz.at</email>
  </overall_contact>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 5, 2019</study_first_submitted>
  <study_first_submitted_qc>October 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2019</study_first_posted>
  <last_update_submitted>October 16, 2019</last_update_submitted>
  <last_update_submitted_qc>October 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

